Skip to content

Author

R. D. de Boer

We have 11 of 1,018 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Oct 2026

Longitudinal burden of disease in hypertrophic cardiomyopathy: one-year follow-up of the AFFECT-HCM study

Over a one-year follow-up period, the QoL remained stable, while the societal costs decreased in both G+/P- individuals and HCM patients, and a significant reduction in BoD was observed among symptomatic oHCM patients, in particular those classified as NYHA III.

R. Mangal, S. Schoonvelde, I. Wiethoff et al. · 0 citations
Open access Oct 2026

Impact of higher comorbidity burden on guideline-directed medical therapy in patients with heart failure with reduced ejection fraction

Patients with a higher comorbidity burden less often used quadruple therapy and had a worse prognosis, as well as its association with clinical outcomes, according to a prespecified subanalysis of the TITRATE-HF registry.

J. J. N. Krabbe, M. I. Wilde, A. Mosterd et al. · 0 citations
Open access Oct 2026

Long-term prognostic value of left ventricular outflow tract gradient in hypertrophic cardiomyopathy

Hypertrophic cardiomyopathy (HCM) is classified as non-obstructive or obstructive, based on the presence of left ventricular outflow tract (LVOT) obstruction. The threshold for obstructive HCM is ≥ 30 mmHg whereas a gradient ≥ 50 mmHg is generally regarded as the threshold for clinically significant obstruction a...

E. Barba, P. Zwetsloot, A. Hirsch et al. · 0 citations
Open access Oct 2026

Impact of age on implementation and tolerability of guideline-directed medical therapy in heart failure with reduced ejection fraction

The need for improved implementation strategies to optimize guideline-directed therapy and dosing levels in the ageing HFrEF population is highlighted, with use of GDMT associated with better clinical outcomes, also among older patients.

J. J. N. Krabbe, M. I. Wilde, W. L. Verloop et al. · 0 citations
Open access Oct 2026

Differential associations of cardiorenal-inflammatory markers with incident cardiovascular disease and cancer in the general population

Elevated levels of cardiorenal-inflammatory markers reflect not only risk of cardiovascular disease (CVD), but also of cancer. The objectives of the current study were to examine whether N-terminal pro-B-type natriuretic peptide (NT-proBNP), urinary albumin excretion (UAE) and high-sensitivity C reactive protein...

Y. Yang, T.-F. Kok, M. Maronier et al. · 0 citations
Open access Sep 2026

Proactive heart failure screening in obesity: design, recruitment, and baseline characteristics of the SCORHFE trial

Abstract Background Obesity is strongly associated with heart failure (HF), but recognition remains challenging in primary care because symptoms, physical findings, and natriuretic peptide concentrations may be difficult to interpret. Objectives To describe the design, recruitment, baseline characteristics, and accepta...

P. A. Motiram, Jie-Fen Chin, E. Rouwet et al. · 0 citations
Open access Sep 2026

Time-Dependent Effects of Inotropic Exposure During Venoarterial Extracorporeal Membrane Oxygenation Support on the Probability of Extracorporeal Membrane Oxygenation Weaning Failure.

OBJECTIVES During venoarterial extracorporeal membrane oxygenation (VA ECMO), organ perfusion no longer entirely depends on native cardiac output, which may reduce the therapeutic advantage of inotropic drugs relative to their risks. We hypothesized that, in this setting, higher cumulative inotropic exposure would be a...

M. V. van Steenwijk, L. Pladet, Atreyu van Esch et al. · 0 citations
Review Open access Aug 2026

Integrating genetics and phenotyping in clinical management of dilated and non-dilated left ventricular cardiomyopathy.

This review paper aims to provide a structured and evidence-informed framework to guide personalized management of DCM and NDLVC, starting from the phenotype towards precision medicine.

R. D. de Boer, A. Chaloupka, Bethan Cowley et al. · 0 citations
Review Aug 2026

Cardioprotective effects of medical therapy for cancer therapy-related cardiac dysfunction: a systematic review and meta-analysis

It is hypothesized that severity of established CTRCD in this subgroup might be too advanced for significant LVEF improvements, and statins hold promise in the prevention of anthracycline- and/or anti-HER2-mediated CTRCD, whereas no beneficial effect was observed in patients with combination regimens.

Y. Appels, R. Parvan, C. G. Mohan et al. · 0 citations
Open access Jul 2026

Differences between men and women in guideline-directed medical therapy implementation, tolerability, and outcomes in heart failure with reduced ejection fraction.

The findings underscore the need for implementation and dosing strategies that account for differences between men and women regarding GDMT implementation, side effects, change in left ventricular ejection fraction (LVEF), and clinical outcomes.

M. I. Wilde, J. J. N. Krabbe, L. J. Bouhuijzen et al. · 0 citations
Review Aug 2026

Impact of cardiovascular disease on cancer incidence and mortality

The manifold of CVD and CV health indicators increase the risk of new-onset cancer and cancer-related mortality, and the need for awareness of future cancer in patients with CVD is emphasized.

L. Yousif, P. Ameri, M. Vinci et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.